Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine, Cytarabine, Venetoclax, and Azacitidine in Higher-risk MDS and CMML
NCT05365035Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cladribine, cytarabine, venetoclax, azacitidine in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2022; status: recruiting.
02
Drugs
cladribinecytarabinevenetoclaxazacitidine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT05365035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05365035.